Bayesian sequential monitoring designs for single-arm clinical trials with multiple outcomes.
about
Monitoring the rates of composite events with censored data in phase II clinical trials.Regulatory perspectives on data monitoring.Using Data Augmentation to Facilitate Conduct of Phase I-II Clinical Trials with Delayed Outcomes.A flexible design for multiple armed screening trials.Safety and activity of lenalidomide and rituximab in untreated indolent lymphoma: an open-label, phase 2 trial.High-dose infusional gemcitabine combined with busulfan and melphalan with autologous stem-cell transplantation in patients with refractory lymphoid malignanciesLenalidomide induces complete and partial remissions in patients with relapsed and refractory chronic lymphocytic leukemiaAdaptive clinical trial designs in oncology.Bayesian sequential monitoring design for two-arm randomized clinical trials with noncompliance.A Bayesian design for phase II clinical trials with delayed responses based on multiple imputation.A proof-of-principle pharmacokinetic, pharmacodynamic, and clinical study with purine nucleoside phosphorylase inhibitor immucillin-H (BCX-1777, forodesine)Phase II clinical trials in oncology: strengths and limitations of two-stage designs.Uracil/ftorafur/leucovorin combined with irinotecan (TEGAFIRI) or oxaliplatin (TEGAFOX) as first-line treatment for metastatic colorectal cancer patients: results of randomised phase II studyA method for utilizing co-primary efficacy outcome measures to screen regimens for activity in two-stage Phase II clinical trials.Idarubicin, cytarabine, and pravastatin as induction therapy for untreated acute myeloid leukemia and high-risk myelodysplastic syndrome.Phase II Trial of Graft-versus-Host Disease Prophylaxis with Post-Transplantation Cyclophosphamide after Reduced-Intensity Busulfan/Fludarabine Conditioning for Hematological Malignancies.Monitoring futility in a two-by-two factorial design: the SPS3 experience.Bayesian designs to account for patient heterogeneity in phase II clinical trials.Treatment-subgroup interaction: an example from a published, phase II clinical trial.Final results of the phase II study of rabbit anti-thymocyte globulin, ciclosporin, methylprednisone, and granulocyte colony-stimulating factor in patients with aplastic anaemia and myelodysplastic syndromePreclinical and early clinical evaluation of the oral AKT inhibitor, MK-2206, for the treatment of acute myelogenous leukemia.Designing studies to find early signals of efficacy.A randomized phase II study of low-dose decitabine versus low-dose azacitidine in lower risk MDS and MDS/MPN.Adaptive Clinical Trials: Overview of Early-Phase Designs and Challenges.A comparison of five approaches to decision-making for a first clinical trial of efficacy.Efficacy of bevacizumab plus erlotinib for advanced hepatocellular carcinoma and predictors of outcome: final results of a phase II trial.Phase 2 study of low-dose clofarabine plus cytarabine for patients with higher-risk myelodysplastic syndrome who have relapsed or are refractory to hypomethylating agents.Adaptive trial of personalized radiotherapy for intrahepatic cancer.Phase II study of rabbit anti-thymocyte globulin, cyclosporine and granulocyte colony-stimulating factor in patients with aplastic anemia and myelodysplastic syndromeA clinical trial for patients with acute myeloid leukemia or myelodysplastic syndromes not eligible for standard clinical trials.Decision-theoretic designs for pre-phase II screening trials in oncology.Decision theoretic designs for phase II clinical trials with multiple outcomes.An extension of Bayesian predictive sample size selection designs for monitoring efficacy and safety.MIDAS: a practical Bayesian design for platform trials with molecularly targeted agents.Bayesian decision theoretic two-stage design in phase II clinical trials with survival endpointOptimizing the concentration and bolus of a drug delivered by continuous infusion.Vosaroxin in combination with decitabine in newly diagnosed older patients with acute myeloid leukemia or high-risk myelodysplastic syndrome.Safety and efficacy of lenalidomide in combination with rituximab in recurrent indolent non-follicular lymphoma: final results of a phase II study conducted by the Fondazione Italiana Linfomi.Bayesian statistical methods.Bayesian two-stage designs for phase II clinical trials.
P2860
Q30679019-903E0632-1442-40FD-ABA3-AC0B268B9C0CQ30731730-C2B4E7AA-4EBA-474C-AC3D-34810BD17376Q30868533-2E4EC03B-A58E-413D-99C1-B4C87C13A9B3Q33181833-DCC545CD-220C-424E-8FB3-28CEB234CB81Q33418964-AAB62F0A-0A3A-40D3-BDAE-5DB6E683422BQ33566475-5A91EFBA-D4C0-45E4-BC82-3272CBCB1E08Q33847401-40503127-9309-4816-AE49-05B2ECDA51B4Q35206844-E918BDC8-6D1B-477E-BBB2-544EE15D1F8DQ35572069-F7508B69-F798-4682-9C9D-94AB73881157Q35619916-FF13C83B-1490-483D-B0C7-11EE094F068CQ35848202-23CA6955-00A6-453C-8B97-71692DDC91B5Q36508078-BE15F697-2E4B-45B5-991D-1E4E05C6EB9AQ36609827-46BC9EEC-527B-49BE-A137-F29E6D302A92Q36687666-DBD4B75A-FE7B-4AA4-B057-0A71BD4C07BAQ36716744-CC90CC4F-3358-4732-9078-E8F390C44E6FQ36779819-20B6DDDB-ED5D-4906-A86D-EF4E3FA14E28Q37064316-25A7DB44-E947-4B0D-B3B4-4D5704467DABQ37182429-990DDC33-231D-4B6E-BDDA-448B226081A7Q37318979-085221FB-D8BD-452B-A5A4-24690D85A542Q37584833-11ED35A7-3504-4083-864B-ED2A342AAF95Q37707078-4EFF834F-861C-4B30-836C-BD5AA1CFECF2Q38052914-19CAFCED-A6FD-4A49-B2D7-C86B8B05D0EAQ38372745-531C6067-FDB8-481C-9F92-49B0D2394DBEQ38697445-79C28DA1-F9DC-4B23-855D-8912568AC094Q39345038-CF9FBD8A-27E6-45B7-B220-E0C10DEE8A53Q39653331-B2DF6513-9DBC-4B10-9572-4669DFC146EAQ40085109-398B4697-7324-411C-8F1D-257AD6E16B62Q40294186-07D3B6D2-7F6B-4CBF-B62F-1411C010028EQ40396357-1D89EA6C-06B5-4396-8625-895BBABF49BCQ40504613-250D18AA-2027-4194-A7CF-786B239CB304Q40669546-6869B445-4351-4816-8613-7C4B2E877B85Q40712207-9747A16E-454A-49BE-8371-5CC9FFF36F5BQ40875025-669A19BA-9A05-4404-89B9-18AE8C41A844Q41662421-9D726559-1704-4F55-965D-682D10D86CDAQ41817333-1FEA4B7C-16D9-4780-B0CD-B17B8153870DQ41978664-2C2C318A-A437-4C4D-823C-79811D4C4211Q42368321-F8CF868F-EC2B-40F4-9BA5-0E10C8A8C991Q42399897-B48492C5-3529-40AC-BBEE-A435B58E7A5DQ43189598-72AD8767-E98D-4048-B18A-BBA872DE6DCAQ44059928-81BE2E50-0BCC-4EAC-B968-584C950A34F8
P2860
Bayesian sequential monitoring designs for single-arm clinical trials with multiple outcomes.
description
1995 nî lūn-bûn
@nan
1995年の論文
@ja
1995年学术文章
@wuu
1995年学术文章
@zh
1995年学术文章
@zh-cn
1995年学术文章
@zh-hans
1995年学术文章
@zh-my
1995年学术文章
@zh-sg
1995年學術文章
@yue
1995年學術文章
@zh-hant
name
Bayesian sequential monitoring ...... trials with multiple outcomes.
@en
Bayesian sequential monitoring ...... trials with multiple outcomes.
@nl
type
label
Bayesian sequential monitoring ...... trials with multiple outcomes.
@en
Bayesian sequential monitoring ...... trials with multiple outcomes.
@nl
prefLabel
Bayesian sequential monitoring ...... trials with multiple outcomes.
@en
Bayesian sequential monitoring ...... trials with multiple outcomes.
@nl
P2093
P356
P1476
Bayesian sequential monitoring ...... trials with multiple outcomes.
@en
P2093
P304
P356
10.1002/SIM.4780140404
P407
P577
1995-02-01T00:00:00Z